NetworkNewsBreaks – Cascadian Therapeutics, Inc. (NASDAQ: CASC) Reports Positive Regulatory Update for Tucatinib in Europe Following EMA Discussion

Cascadian Therapeutics (NASDAQ: CASC) this morning reported a positive outcome from recent discussions with the European Medicines Agency (EMA) regarding the development of the company’s investigational medicine for the treatment of HER2-positive metastatic breast cancer, tucatinib. The company has received validating news that if the ongoing pivotal trial of tucatinib known as HER2CLIMB demonstrates positive results, it could serve as a single registrational trial for submission of a Marketing Authorization Application (MAA) to the EMA and potential marketing approval. Cascadian received a similar confirmation from the FDA last year. “This is an important milestone for the company. We had anticipated providing an update on our European regulatory strategy later this year; and we are pleased with this early feedback from the EMA that the current design of the global HER2CLIMB trial, if positive, could support approval and a potentially shorter path to the European market for tucatinib. Site and patient enrollment is currently ahead of schedule in North America, and we are now poised to begin enrolling patients in HER2CLIMB in other countries,” Cascadian Therapeutics president and CEO Scott Myers stated in the news release.

To view the full press release, visit:

About Cascadian Therapeutics

Cascadian Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative product candidates for the treatment of cancer. Its lead product candidate, tucatinib, is an investigational oral, selective small molecule HER2 inhibitor. Cascadian Therapeutics is conducting a randomized, double-blind controlled pivotal clinical trial called HER2CLIMB, which is comparing tucatinib vs. placebo, each in combination with capecitabine and trastuzumab, in patients with locally advanced or metastatic HER2-positive breast cancer with and without brain metastases, who have previously been treated with a taxane, trastuzumab, pertuzumab and T-DM1. For more information, please visit

About NetworkNewsBreaks

NetworkNewsBreaks (NNB) provide a rapid summary of corporate news that caught the attention of NetworkNewsWire (NNW). NNB keeps you up-to-date on active US Public Companies complementary to NNW’s broader scope as a provider of news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published:

NetworkNewsWire (NNW)
New York, New York
212.418.1217 Office

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s